# Niraparib and Temozolomide in Patients Glioblastoma

> **NCT06258018** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Armando Santoro, MD** · enrollment: 86 (estimated)

## Conditions studied

- Glioma, Malignant

## Interventions

- **DRUG:** Temodal
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT06258018
- **Lead sponsor:** Armando Santoro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09
- **Primary completion:** 2026-12
- **Final completion:** 2027-09
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2024-08-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06258018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06258018, "Niraparib and Temozolomide in Patients Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06258018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*